Treatment of relapsing polychondritis with the TNF-alpha antagonist adalimumab

Tobias Lahmer, Andreas Knopf, Matthias Treiber, Uwe Heemann, Klaus Thuermel

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Relapsing polychondritis (RP) is a rare immune-mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially, the cartilaginous structures of ear, respiratory tract, nose, and joints are affected. Around 30% of the cases are associated with other diseases especially systemic vasculitis. Onset of RP is most likely between the ages of 40-60 years. This case reports the often disguised and similar symptoms of RP to Wegner's granulomatosis and the challenge of diagnosis. The relative rarity of RP has not permitted clinical trials to determine the efficacy and safety of different therapies. Current treatment is largely empiric and based on case reports. In this case, we successfully used a treatment with the TNF-alpha antagonist adalimumab.

Original languageEnglish
Pages (from-to)1331-1334
Number of pages4
JournalClinical Rheumatology
Volume29
Issue number11
DOIs
StatePublished - Nov 2010

Keywords

  • Auricular chondritis
  • Autoimmune disease
  • Cartilage disorder
  • McAdams criteria
  • Relapsing polychondritis
  • TNF-alpha antagonists

Fingerprint

Dive into the research topics of 'Treatment of relapsing polychondritis with the TNF-alpha antagonist adalimumab'. Together they form a unique fingerprint.

Cite this